D-121 is under clinical development by Oblita Therapeutics and currently in Phase I for Leishmaniasis (Kala-Azar). According to GlobalData, Phase I drugs for Leishmaniasis (Kala-Azar) have a 56% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how D-121’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
D-121 overview
D-121 (Oleylphosphocholine) is under development for the treatment of cutaneous, visceral and muco-leishmaniasis, Chagas disease, cryptosporidiosis caused by Cryptosporidium parvum and invasive fungal infections (IFIs). The drug candidate is administered through oral route. It is one of the representatives of the class hexadecylphosphocholine (Alkylphosphocholines family). The drug candidate is a new chemical entity.
Oblita Therapeutics overview
Oblita Therapeutics is a drug discovery and development company. It develops drugs for the treatment of neglected diseases. The company’s lead candidate, oleylphosphocholine is a new chemical entity (NCE) for the treatment of leishmaniasis an infectious disease caused by sand flies that is in Phase I clinical trial. It is also under evaluation for the treatment of various infectious diseases such as Chagas disease, fungal infections, invasive fungal infections (IFIs) and cryptosporidium infection. Oblita Therapeutics intends to harness its capabilities in clinical research management and regulatory management to develop drugs for neglected diseases. Oblita Therapeutics is headquartered in Zoersel, Belgium.
For a complete picture of D-121’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
